

Haematologica
HAEMATOL/2019/236133
Version 3

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA

Audrey Belot, Ophélie Gourbeyre, Alexis Fay, Anais Palin, Céline Besson, Chloé Latour, Corey R. Hopkins, George F. Tidmarsh, Hélène Coppin, Marie-Paule Roth, Matthew R. Ritter, Charles C. Hong, and Delphine Meynard

Disclosures: D.M. was supported by the Cooley's Anemia Foundation, the French Foundation for Rare Diseases, the Région Midi-Pyrénées and ANR (ANR-17-CE14-0036-01 and ANR-17-CE14-0031-01). H.C. and M.-P.R. were supported in part by grants from FRM (DEQ2000326528) and ANR (ANR-13-BSV3-0015-01). This work was also supported by the "Programme des Investissements d'Avenir" ANINFIMIP (ANR-11EQPX-0003). CRH and CCH are inventors of LJ00328, which has been licensed to La Jolla Pharmaceutical Company (LJPC), and GFT and MRR are employees of LJPC. DM received Research Funding from LJPC. The other authors have no conflict of interest to declare.

Contributions: A.B. performed experiments, analyzed, and discussed results; O.G., A.F., A.P., C.B.-F., and C.L. performed experiments; C.R.H, G.F.T, M.R.R and C.C.H. analyzed and discussed results; H.C, and M.-P.R. discussed data and wrote the manuscript; D.M. designed research, analyzed and discussed data, and wrote the manuscript; and all authors reviewed and approved the final manuscript.